Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.63 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | 13.49 | — | — | — | 5.58 | 24.44 | — | — | 156.64 | — |
| — | — | — | — | — | — | — | — | — | — | — | +141.6% | — | — | — | -96.4% | — | — | — | -62.9% | — | |
| P/B Ratio | 0.25 | 1.28 | 0.95 | 3.88 | 2.55 | 0.66 | 2.35 | 1.82 | 1.65 | 1.47 | 0.94 | 8.22 | 3.13 | 1.37 | 0.88 | — | — | 18.23 | 6.14 | 4.76 | 2.64 |
| — | +93.9% | -59.5% | +113.8% | +54.9% | -55.2% | +150.5% | -77.9% | -47.3% | +7.5% | +6.6% | — | — | -92.5% | -85.7% | — | — | +536.2% | +115.1% | +46.3% | -74.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 12.1% | 32.1% | — | — | -84.4% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +114.3% | — | — | — | +68.4% | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -1809.0% | — | — | — | -836.3% | -1785.0% | — | — | -8384.8% | — |
| — | — | — | — | — | — | — | — | — | — | — | -116.3% | — | — | — | +90.0% | — | — | — | -25.2% | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -1636.6% | — | — | — | -406.8% | -1876.8% | — | — | -8698.0% | — |
| — | — | — | — | — | — | — | — | — | — | — | -302.4% | — | — | — | +95.3% | — | — | — | -22.8% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -235.5% | -17.3% | -40.8% | -67.4% | -44.9% | -53.7% | -99.3% | -83.7% | -59.4% | -36.6% | -77.7% | -116.4% | -54.0% | -33.2% | -133.6% | — | — | -126.3% | -44.2% | -50.3% | -36.5% |
| — | +67.7% | +58.9% | +19.5% | +24.4% | -46.8% | -27.8% | +28.1% | -10.1% | -10.2% | +41.8% | — | — | +73.7% | -202.0% | — | — | -439.7% | -283.8% | -124.0% | +63.3% | |
| ROA | -121.7% | -11.2% | -22.8% | -35.0% | -28.2% | -29.7% | -40.0% | -38.7% | -30.7% | -16.9% | -18.4% | -21.5% | -17.3% | -13.2% | -12.9% | -8.2% | -23.3% | -16.9% | -10.6% | -17.2% | -16.6% |
| — | +62.3% | +43.0% | +9.7% | +8.2% | -75.6% | -118.0% | -80.6% | -78.1% | -27.7% | -41.9% | -160.3% | +25.9% | +21.5% | -21.9% | +52.1% | -40.1% | -39.4% | -71.1% | -87.4% | +50.3% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.04 | 0.05 | 0.11 | 0.07 | 0.05 | 0.22 | 0.02 | 0.36 | 0.37 | 0.84 | 4.17 | 1.39 | 0.75 | 0.54 | — | — | 9.94 | 2.44 | 1.51 | 0.93 |
| — | -13.6% | -79.8% | +388.6% | -81.2% | -86.3% | -73.3% | -99.5% | -74.0% | -50.7% | +56.0% | — | — | -92.4% | -77.9% | — | — | +1398.7% | +280.7% | +150.4% | -66.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.39 | 3.00 | 2.77 | 1.81 | 2.39 | 3.18 | 1.47 | 1.85 | 1.82 | 2.28 | 1.52 | 1.08 | 1.55 | 1.99 | 2.34 | 0.94 | 0.84 | 1.81 | 2.36 | 3.25 | 4.22 |
| — | -5.8% | +89.0% | -1.9% | +31.4% | +39.8% | -3.6% | +70.5% | +17.8% | +14.5% | -35.0% | +15.0% | +84.3% | +9.8% | -0.7% | -71.0% | -80.1% | -70.5% | -66.9% | -55.3% | +31.9% | |
| Quick Ratio | 2.39 | 3.00 | 2.77 | 1.81 | 2.39 | 3.18 | 1.47 | 1.85 | 1.82 | 2.28 | 1.52 | 1.08 | 1.55 | 1.99 | 2.34 | 0.94 | 0.84 | 1.81 | 2.36 | 3.25 | 4.22 |
| — | -5.8% | +89.0% | -1.9% | +31.4% | +39.8% | -3.6% | +70.5% | +17.8% | +14.5% | -35.0% | +15.0% | +84.3% | +9.8% | -0.7% | -71.0% | -80.1% | -70.5% | -66.9% | -55.3% | +31.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -26.98 | -18.22 | -19.76 | -14.32 | -15.48 | -20.00 | -20.62 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNGX stock.
Soligenix, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Soligenix, Inc.'s business trajectory between earnings reports.